EGFR and breast cancer: Poziotinib was terminated in 3 clinical studies for NSCLC (patients having EGFR or HER2 exon 20 insertion mutation), breast cancer (In HER2+ breast cancer patients, poziotinib in combination with T-DM1) and adenocarcinoma of lung stage IIIB and IV [108,109,110].